• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacology, Biochemistry and Behavior >Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology
【24h】

Amitifadine, a triple monoamine uptake inhibitor, reduces binge drinking and negative affect in an animal model of co-occurring alcoholism and depression symptomatology

机译：三联单胺摄取抑制剂阿米替丁在同时发生的酗酒和抑郁症状动物模型中减少狂饮和负面影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The co-occurrence of alcoholism and depression is highly prevalent and difficult to treat. In an animal model of binge drinking that exhibits abstinence-induced behaviors reminiscent of negative affective states, the triple monoamine uptake inhibitor, amitifadine, produced a selective, dose dependent attenuation of binge drinking. Amitifadine also reversed abstinence-induced increases in the intracranial self-stimulation threshold, a model of anhedonia, and immobility in the forced swim test, reflecting behavioral despair. In view of the safety profile of amitifadine in humans, including low risk for weight gain, lack of sexual side effects, and low potential for abuse, we hypothesize that amitifadine will be effective in treating co-occurring alcoholism and depression.
机译：酗酒和抑郁症并存的现象非常普遍，难以治疗。在暴饮酒的动物模型中，它表现出禁欲诱导的行为，使人联想到负面的情绪状态，三重单胺摄取抑制剂阿米替丁可选择性地抑制剂量，从而抑制了暴饮酒。阿米替丁还逆转了禁欲引起的颅内自我刺激阈值的升高，这是一种快感缺乏症，并且在强迫游泳试验中不活动，反映出行为上的绝望。考虑到阿米替丁在人类中的安全性，包括体重增加的风险低，缺乏性副作用以及滥用的可能性低，我们假设阿米替丁可以有效地治疗酒精中毒和抑郁症。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号